Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab for induction and maintenance therapy in moderately to severely active ulcerative colitis
2023-505678-14-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 2, randomised trial of lutikizumab in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoint: Endoscopic improvement at week 12. Planned start Aug 2024; status: authorised.
02
Drugs
lutikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-505678-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505678-14-00.